Virbac SA (0NM7) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Virbac SA €231, price €309, upside -25.4%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Virbac SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €216.44 – €434.01 · fair‑value band €152.58 – €317.02 · the €309.00 price screens above the €230.67 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific.
Show more
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Stock analysis
Virbac SA (0NM7) currently trades at €309.00, while our model-based Fair Value estimate is €230.67, 25.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €255.96 per share, and 3 of the 23 models we run sit above the €309.00 price.
Bear case: the Asset-Based group reads lowest at €44.07, and 20 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: €152.58 (bear) to €317.02 (bull), the price of €309.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Virbac SA reported revenue of €934M in FY2020 versus €872M in FY2016, a compound +1.7%/yr. Reported net income was €137M in FY2020, compounding +41.1%/yr from FY2016.
Key figures
Market cap €2.9B · P/S ratio 2.00 · Dividend yield 0.5% · Net margin 14.7% · Return on equity 13.9% · Return on assets (EBIT) 7.7% · Operating margin 13.5% · Revenue (TTM) €1.5B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −25%, 0NM7 screens richer than that median.
Fair Value models
Bear €152.58Fair Value €230.67Bull €317.02
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
7.9% (2016) → 19.9% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Above median
Fair Value upside−31.2% · Below median
Profitability
Return on equity (TTM)13.9% · Above median
Return on assets7.7% · Above median
Net margin (TTM)10.3% · Below median
Operating margin (TTM)13.5% · Below median
Growth and dividend
Revenue growth4.6% · Below median
Dividend yield (TTM)0.5% · Bottom 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Virbac SA Fair Value". https://www.fairvalue-calculator.com/stock/0NM7
Frequently asked questions
Is Virbac SA (0NM7) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €230.67 versus a price of €309.00, about −25% upside (overvalued).
What is the fair value of 0NM7?
Our model-based fair value for Virbac SA is €230.67 (as of Sep 24, 2026), built from audited fundamentals. The current price: €309.00.
What is the quality score of 0NM7?
Virbac SA has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Virbac SA (0NM7)?
Our model-based price target is the fair value of €230.67 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario €152.58, optimistic scenario €317.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Virbac SA stock forecast for 2026?
Our models put fair value at €230.67, about −25% upside versus a price of €309.00 (overvalued). Cautious scenario €152.58, optimistic scenario €317.02. The calculation is refreshed regularly with new filings.
What is the revenue of Virbac SA (0NM7)?
Virbac SA reported trailing-twelve-month revenue of about €1.5B (latest available figure, as of Sep 24, 2026).
Does Virbac SA pay a dividend?
Virbac SA currently shows a dividend yield of about 0.47% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Virbac SA (0NM7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Virbac SA it is €230.67 per share (as of Sep 24, 2026), against a price of €309.00. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Virbac SA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0NM7 trades above its calculated fair value: price €309.00, fair value €230.67, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0NM7?
No. The price is what the market pays today (€309.00); the fair value is what the company's own numbers justify (€230.67). For Virbac SA the two are €78.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Virbac SA worth?
The market values Virbac SA at about €2.9B (market capitalisation, as of Sep 24, 2026). Per share that is €309.00; our models calculate a fair value of €230.67 per share.
What do the bullish and bearish scenarios say about 0NM7?
Our models span a range for Virbac SA: cautious scenario €152.58, base €230.67, optimistic €317.02 per share (as of Sep 24, 2026, price €309.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Virbac SA (0NM7)?
Balance-sheet figures for Virbac SA (as of Sep 24, 2026): return on equity 13.9%, debt of 0.08 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is 0NM7 from its 52-week high?
Virbac SA trades at €309.00, about 19% below its 52-week high of €383.82 and 2% above the low of €302.25 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €230.67 is for.
Which stocks are comparable to Virbac SA?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Virbac SA stock attractive at the current price?
The data as of Sep 24, 2026: price €309.00, calculated fair value €230.67 (−25%), Quality Score 67/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0NM7 calculated?
We run Virbac SA through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €230.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Virbac SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Virbac SA (0NM7)?
The closing price on Oct 2, 2026 was €309.00. Our model-based fair value is €230.67, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Virbac SA right now?
Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€152.58 to €317.02) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Virbac SA
How large is the market capitalisation of Virbac SA (0NM7)?
The market capitalisation of Virbac SA is €2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Virbac SA (0NM7)?
The price-to-sales ratio of Virbac SA is 2.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Virbac SA (0NM7)?
The dividend yield of Virbac SA is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Virbac SA (0NM7)?
The net margin of Virbac SA is 14.7% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Virbac SA (0NM7)?
The return on equity (ROE) of Virbac SA is 13.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Virbac SA (0NM7)?
On an EBIT basis the return on assets of Virbac SA is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Virbac SA (0NM7)?
The operating margin of Virbac SA is 13.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Virbac SA (0NM7)?
Revenue at Virbac SA is growing +4.6% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Virbac SA (0NM7)?
Earnings per share at Virbac SA are growing +35.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Virbac SA in the live analysis
One click puts Virbac SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
